TR201908429T4 - Tiyotropyum içeren solunabilir ilaç. - Google Patents

Tiyotropyum içeren solunabilir ilaç. Download PDF

Info

Publication number
TR201908429T4
TR201908429T4 TR2019/08429T TR201908429T TR201908429T4 TR 201908429 T4 TR201908429 T4 TR 201908429T4 TR 2019/08429 T TR2019/08429 T TR 2019/08429T TR 201908429 T TR201908429 T TR 201908429T TR 201908429 T4 TR201908429 T4 TR 201908429T4
Authority
TR
Turkey
Prior art keywords
medicine containing
formulation
containing tiotropium
inhalable medicine
percentages
Prior art date
Application number
TR2019/08429T
Other languages
English (en)
Inventor
Zeng Xian-Ming
Original Assignee
Teva Branded Pharmaceutical Prod R & D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45813952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201908429(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Prod R & D Inc filed Critical Teva Branded Pharmaceutical Prod R & D Inc
Publication of TR201908429T4 publication Critical patent/TR201908429T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bu buluş, bir tiyotropyum tuzu, %12-20 etanol, %0,1-1,5 su, %0,05-0,10 sitrik asit (veya başka bir organik asit) ve bir HFA itici gazı içeren bir solüsyon formülasyonu ile ilgilidir, burada yüzdeler, formülasyonun toplam ağırlığına bağlı olarak ağırlıkça yüzdelerdir. Buluş, ayrıca formülasyonu ihtiva eden bir kutuyu içeren bir pMDI'yi sağlar.
TR2019/08429T 2011-12-19 2012-12-06 Tiyotropyum içeren solunabilir ilaç. TR201908429T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577315P 2011-12-19 2011-12-19
GBGB1200525.2A GB201200525D0 (en) 2011-12-19 2012-01-13 An inhalable medicament

Publications (1)

Publication Number Publication Date
TR201908429T4 true TR201908429T4 (tr) 2019-07-22

Family

ID=45813952

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/08429T TR201908429T4 (tr) 2011-12-19 2012-12-06 Tiyotropyum içeren solunabilir ilaç.

Country Status (29)

Country Link
US (1) US9655969B2 (tr)
EP (3) EP2793886B1 (tr)
JP (1) JP5791166B2 (tr)
KR (2) KR101670564B1 (tr)
CN (1) CN103998039A (tr)
AR (1) AR089302A1 (tr)
AU (1) AU2012358475B2 (tr)
BR (1) BR112014014535A2 (tr)
CA (1) CA2856047C (tr)
CY (1) CY1116142T1 (tr)
DK (3) DK3143998T3 (tr)
EA (1) EA028461B1 (tr)
ES (3) ES2728940T3 (tr)
GB (1) GB201200525D0 (tr)
HK (2) HK1198512A1 (tr)
HR (1) HRP20141176T1 (tr)
HU (2) HUE044647T2 (tr)
IL (1) IL232946A0 (tr)
MX (1) MX361925B (tr)
PL (3) PL3143998T3 (tr)
PT (1) PT2606891E (tr)
RS (1) RS53783B1 (tr)
SI (1) SI2606891T1 (tr)
SM (1) SMT201400192B (tr)
TR (1) TR201908429T4 (tr)
TW (1) TWI468187B (tr)
UY (1) UY34525A (tr)
WO (1) WO2013092237A1 (tr)
ZA (2) ZA201403041B (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340264B (es) 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung
DK2897588T3 (da) * 2013-11-22 2019-08-12 Teva Branded Pharmaceutical Products R&D Inc Inhalerbart lægemiddel
PL2897589T3 (pl) * 2013-11-22 2018-06-29 Teva Branded Pharmaceutical Products R & D, Inc. Lek do inhalacji
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US20190054010A1 (en) * 2015-10-29 2019-02-21 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
EP3515439B1 (en) * 2016-09-19 2021-12-15 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
US12220525B2 (en) 2018-06-27 2025-02-11 Kindeva Drug Deliver L.P. Tiotropium formulation and inhaler
WO2026047392A1 (en) 2024-08-26 2026-03-05 Glenmark Specialty S.A. A pressurized inhalation composition of tiotropium
US12558314B1 (en) 2024-08-26 2026-02-24 Glenmark Specialty S.A. Pressurized inhalation composition of tiotropium

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9026191D0 (en) 1990-12-01 1991-01-16 Harris Pharma Ltd Breath actuated dispensing device
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB2264238A (en) 1992-05-29 1993-08-25 Norton Healthcare Ltd Medicament inhalor device
EP0673240B1 (en) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
EP1238661A1 (en) 1999-10-12 2002-09-11 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
US6553988B1 (en) 2000-06-09 2003-04-29 Norton Healthcare, Inc. Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber
PL200063B1 (pl) 2000-10-12 2008-12-31 Boehringer Ingelheim Pharma Nowe proszki do inhalacji zawierające tiotropium
DE50103666D1 (de) 2000-10-12 2004-10-21 Boehringer Ingelheim Pharma Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
US20030070679A1 (en) 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
DE10126924A1 (de) 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalationskapseln
PL208137B1 (pl) 2001-06-22 2011-03-31 Boehringer Ingelheim Pharma Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10214263A1 (de) 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050058606A1 (en) 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
EP1575588A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
CA2576410A1 (en) 2003-09-18 2006-03-31 Norton Healthcare Ltd. Particles
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
CN100509809C (zh) 2003-11-03 2009-07-08 贝林格尔·英格海姆国际有限公司 具有抗胆碱能作用的新颖无水晶体
SE0303570L (sv) 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
JP2007528409A (ja) 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
US20060079544A1 (en) 2004-08-13 2006-04-13 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
SG159550A1 (en) * 2005-02-25 2010-03-30 Chiesi Farma Spa Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
EP1879888A2 (en) 2005-05-02 2008-01-23 Boehringer Ingelheim International GmbH Crystalline forms of tiotropium bromide
JP5227790B2 (ja) 2005-05-02 2013-07-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規結晶性臭化チオトロピウム
RU2418796C2 (ru) 2005-06-15 2011-05-20 Берингер Ингельхайм Интернациональ Гмбх Способ получения новых солей тиотропия
KR20080039974A (ko) 2005-08-06 2008-05-07 베링거 인겔하임 인터내셔날 게엠베하 중증 지속성 천식의 치료에서 티오트로퓸 염의 용도
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
KR101395881B1 (ko) 2005-12-19 2014-05-21 시코르, 인크. 브롬화 티오트로피움의 신규한 형태 및 이의 제조 방법
EP1923393A1 (en) 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
US8889213B2 (en) 2009-01-26 2014-11-18 Teva Pharmaceutical Industries Ltd. Processes for coating a carrier with microparticles
WO2011061498A2 (en) * 2009-11-17 2011-05-26 Cipla Limited Inhalation solutions
HRP20150452T1 (hr) 2010-10-12 2015-08-14 Ivax Pharmaceuticals Ireland Ureä�aj za sprej za nos
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
EP2819669B1 (de) 2012-02-28 2021-04-21 Boehringer Ingelheim International GmbH Neue treibgashaltige tiotropium-formulierung

Also Published As

Publication number Publication date
HK1200343A1 (en) 2015-08-07
WO2013092237A1 (en) 2013-06-27
RS53783B1 (sr) 2015-06-30
UY34525A (es) 2014-07-31
KR20160111539A (ko) 2016-09-26
AU2012358475A8 (en) 2014-06-26
AU2012358475A1 (en) 2014-05-22
DK3143998T3 (da) 2019-06-17
ES2526685T3 (es) 2015-01-14
ZA201403041B (en) 2015-11-25
HRP20141176T1 (hr) 2015-03-13
TW201332587A (zh) 2013-08-16
EP2606891B1 (en) 2014-11-05
ES2602314T3 (es) 2017-02-20
TWI468187B (zh) 2015-01-11
HUE030983T2 (en) 2017-06-28
PL2606891T3 (pl) 2015-07-31
CA2856047A1 (en) 2013-06-27
US20140348758A1 (en) 2014-11-27
HK1198512A1 (en) 2015-05-15
US9655969B2 (en) 2017-05-23
AR089302A1 (es) 2014-08-13
CN103998039A (zh) 2014-08-20
CA2856047C (en) 2017-01-03
SI2606891T1 (sl) 2015-04-30
ES2728940T3 (es) 2019-10-29
PL3143998T3 (pl) 2019-09-30
EA201491206A1 (ru) 2014-12-30
HUE044647T2 (hu) 2019-11-28
KR20140097481A (ko) 2014-08-06
EP3143998B1 (en) 2019-05-22
ZA201501986B (en) 2016-10-26
IL232946A0 (en) 2014-07-31
KR101670564B1 (ko) 2016-10-28
EP2793886B1 (en) 2016-08-24
BR112014014535A2 (pt) 2017-06-13
PL2793886T3 (pl) 2017-06-30
NZ624161A (en) 2015-08-28
PT2606891E (pt) 2015-01-05
JP2015500224A (ja) 2015-01-05
GB201200525D0 (en) 2012-02-29
EP2793886A1 (en) 2014-10-29
MX2014007357A (es) 2014-08-21
AU2012358475B2 (en) 2015-08-20
EP2606891A1 (en) 2013-06-26
SMT201400192B (it) 2015-03-05
MX361925B (es) 2018-12-19
EA028461B1 (ru) 2017-11-30
DK2606891T3 (en) 2015-01-05
CY1116142T1 (el) 2017-03-15
DK2793886T3 (en) 2016-12-05
EP3143998A1 (en) 2017-03-22
JP5791166B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
AU2012358475A8 (en) An inhalable medicament comprising tiotropium
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
PH12012502352A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
MX2013011774A (es) Derivados de acido 3-fenilpropionico ramificados y su uso.
TR201905814T4 (tr) Jak inhibitörü olarak bipirazol tuzu.
BR112015012555A2 (pt) derivados de benzimidazol como antagonistas de ep4
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112016010080A8 (pt) compostos de pirazolopirimidina, composição farmacêutica e seu uso
EA201270216A1 (ru) Фармацевтический состав
MX339033B (es) Derivados de acido antranilico.
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112013032758A2 (pt) derivados de n-oxi-pirazolo-triazepino-diona
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
MY170262A (en) Dicarboxylic acid compound
CA2920410C (en) Thienopiperidine derivative and use thereof
BR112015001207A2 (pt) derivados de carbamato/ureia
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
MY161280A (en) Topical antifungal agent
CY1113228T1 (el) Τριαζολοπυριδαζινες ως αναστολεις ραr1, η παρασκευη και η χρηση τους ως φαρμακα
WO2011098408A3 (de) Hydrazin-substituierte anthranilsäurederivate
UA116877C2 (uk) Сполука з антибактеріальною і/абопротивірусною активністю